CLEA Japan Academic Presentation Archive：ATTD-ASIA 2025

2025/09/16

SGLT2 INHIBITION IMPROVES GLYCEMIC CONTROL, DIABETIC NEPHROPATHY AND NEUROPATHY IN THE SPONTANEOUSLY DIABETIC TORII FATTY RAT, A TRANSLATIONAL MODEL OF TYPE 2 DIABETES

Key Word：
Spontaneously Diabetic Torii (SDT) fatty rat, SGLT2 inhibitor, Diabetic nephropathy, Diabetic neuropathy

François Briand^１、Estelle Grasset^１、Takeshi Ohta^２、Masami Shinohara^３、Caroline Dubroca^４、Thierry Sulpice^１^４

^１Physiogenex, FRANCE、^２Graduate School of Agriculture, Kyoto University, JAPAN、^３CLEA Japan Inc, JAPAN、^４Cardiomedex, FRANCE

Announcement: e-Poster Presentation at ATTD-ASIA 2025

We are pleased to present our research on the Spontaneously Diabetic Torii (SDT) fatty rat model at ATTD-ASIA 2025 in Singapore. This preclinical type 2 diabetes model uniquely develops both diabetic nephropathy and neuropathy, addressing a critical gap in current drug discovery efforts.

Our study demonstrates that SGLT2 inhibition with dapagliflozin significantly improves glycemic control, kidney function, and nerve health in this model. These findings highlight the SDT fatty rat as a valuable tool for evaluating new diabetes therapies.

This work is highly relevant for researchers in diabetes, nephropathy, neuropathy, and pharmaceutical development. We invite you to explore our e-poster at the conference.

For more information or collaboration inquiries, please reach out via LinkedIn.